The U.S. Food and Drug Administration granted accelerated approval to Vera Therapeutics’ Trutakna, also known as atacicept-vymj, on July 7, 2026. The once-weekly, self-administered injection is approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, or IgAN, who are at risk of disease progression. Vera set the wholesale acquisition cost at $32,700 for a 28-day supply, equivalent to approximately $425,000 per year.
IgAN is a progressive autoimmune kidney disease in which abnormal immunoglobulin A deposits accumulate in the kidneys, causing inflammation and potentially leading to kidney failure. Trutakna is particularly important because it is the first FDA-approved treatment to target both BAFF and APRIL, two immune-system proteins involved in the production and survival of the cells that generate disease-causing antibodies.
The approval was based on a reduction in proteinuria, rather than definitive evidence that the medicine can prevent long-term kidney-function decline. In Vera’s clinical program, treatment produced an approximately 42% reduction in urinary protein levels compared with placebo, while proteinuria fell about 46% from baseline over 36 weeks. The FDA has therefore required confirmatory evidence, and continued approval may depend on whether later data verify a meaningful clinical benefit.
That distinction matters. Proteinuria is an accepted indicator of kidney damage and an important predictor of disease progression, but it is still a surrogate endpoint. Patients, physicians and insurers will ultimately want to know whether Trutakna can delay dialysis, transplantation and irreversible loss of kidney function. The drug’s commercial success may therefore depend as much on upcoming kidney-function data as on the initial approval.
The price will also attract attention. At $425,000 annually, Trutakna enters a specialty-drug market in which manufacturers argue that targeted treatments can prevent much more expensive long-term complications. Payers, however, are likely to impose eligibility requirements and demand clear evidence that the treatment delivers benefits beyond reducing laboratory measurements.
Competition in IgAN is already intensifying. Vera will face treatments from companies including Novartis, Otsuka Pharmaceutical and Travere Therapeutics, while other developers are advancing medicines aimed at similar immune pathways. Trutakna has the advantage of being the first approved dual BAFF-and-APRIL inhibitor, but it is entering a market that is becoming increasingly crowded rather than one with no alternatives.
